1. Home
  2. CXAI vs CRIS Comparison

CXAI vs CRIS Comparison

Compare CXAI & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CXApp Inc.

CXAI

CXApp Inc.

HOLD

Current Price

$0.23

Market Cap

8.9M

Sector

Technology

ML Signal

HOLD

Logo Curis Inc.

CRIS

Curis Inc.

HOLD

Current Price

$1.00

Market Cap

12.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CXAI
CRIS
Founded
N/A
2000
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.9M
12.9M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
CXAI
CRIS
Price
$0.23
$1.00
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$16.50
AVG Volume (30 Days)
8.4M
385.3K
Earning Date
11-12-2025
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,222,000.00
$11,650,000.00
Revenue This Year
N/A
$6.13
Revenue Next Year
$70.21
$7.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
13.56
52 Week Low
$0.21
$0.77
52 Week High
$1.69
$3.41

Technical Indicators

Market Signals
Indicator
CXAI
CRIS
Relative Strength Index (RSI) 36.78 52.86
Support Level $0.21 $0.82
Resistance Level $0.34 $0.96
Average True Range (ATR) 0.05 0.08
MACD -0.00 0.02
Stochastic Oscillator 10.57 73.00

Price Performance

Historical Comparison
CXAI
CRIS

About CXAI CXApp Inc.

CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, and CXAI-VU. The company generates the majority of its revenue from Licenses.

About CRIS Curis Inc.

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Share on Social Networks: